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Sedative	load	and	frailty	among	community‐dwelling	1 
population	aged	≥65	years	2 
	3 
Abstract	4 
Objective:	To	explore	the	association	between	use	of	sedative	drugs	and	frailty.	5 
Design:	Cross‐sectional	study.	6 
Setting:	First	wave	of	The	Irish	Longitudinal	Study	on	Ageing	(TILDA),	a	nationally	7 
representative	cohort	of	the	community‐dwelling	population	aged	≥50	years	in	Ireland.	8 
Participants:	1,642	men	and	1,804	women	aged	≥65	years.	9 
Measurements:	 Regular	 use	 of	 sedative	 drugs	 determined	 according	 to	 the	 sedative	 load	10 
model,	 frailty	 phenotype	 status	 and	 frailty	 deficit	 index	 (FI)	 score	 assessed	 using	 validated,	11 
established	protocols.	12 
	13 
Results:	Overall,	19%	of	 the	participants	 took	sedative	drugs,	most	 frequently	hypnotics	and	14 
antidepressants.		Sedative	drug	use	was	at	46%	for	frail,	23%	for	prefrail	and	9%	for	non‐frail	15 
participants.	After	adjustment	for	covariates,	sedative	load	was	positively	associated	with	being	16 
prefrail	(OR=1.27;	95%	CI	1.11‐1.46)	and	frail	(OR=1.30;	95%	CI	1.02‐1.64).	Advancing	age	but	17 
not	 sex	 remained	 significant	 (p<0.001).	 After	 adjustment	 for	 covariates,	 the	 association	18 
between	sedative	load	and	the	frailty	deficit	index	(FI)	was	also	significant	at	p≤0.001	(β	=1.77;	19 
95%	CI	1.13‐2.42).	20 
	21 
Conclusion:	 Higher	 sedative	 load	 was	 positively	 associated	 with	 phenotype	 frailty	 and	 the	22 
frailty	deficit	 index.	This	 suggests	 that	 careful	 consideration	must	be	given	when	prescribing	23 
sedatives	to	frail	older	adults,	who	are	most	vulnerable	to	adverse	drug	reactions	and	adverse	24 
health	outcomes.		25 
		26 
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INTRODUCTION	31 
Older	people	are	susceptible	to	adverse	drug	events	owing	to	the	diminishing	physiological	32 
reserve	associated	with	ageing.1	This	can	be	exacerbated	further	by	acute	or	chronic	diseases	and	33 
by	 the	 drugs	 used	 to	 treat	 them.2	 Older	 populations	 are	 often	 prescribed	 a	 range	 of	 drugs	with	34 
sedative	properties	(e.g.	psychotropics).3	Sedation	 is	defined	as	subjective	 feelings	of	drowsiness	35 
and	 sleepiness,	 but	 also	 as	 decreased	 psychomotor	 functioning,	 which	 can	 be	 measured	 in	36 
objective	 tests.4	 Sedative	drugs	have	been	associated	with	 falls,	 fractures,	physical	 and	 cognitive	37 
impairment	and	disability	among	community‐dwelling	older	people.3,5,6,7		38 
With	 more	 drugs	 being	 taken	 concomitantly,	 the	 risk	 of	 interactions	 and	 cumulative	39 
sedative	 effects	 is	 increased1,8,9,	 leading	 to	 the	 development	 of	 different	 models	 to	 study	 the	40 
sedative	 effect	 of	 drugs.10	 The	 “sedative	 load	model”	 was	 developed	 to	 quantify	 the	 cumulative	41 
effect	 of	 taking	multiple	 drugs	with	 sedative	 properties.11	Older age, female sex, lower education 42 
levels, impaired mobility depression and dementia are predictors of sedative load exposure. 3,8	43 
The	 global	 expansion	 of	 population	 ageing	 has	 lead	 to	 the	 clinical	 condition	 of	 frailty	44 
becoming	 an	 increasing	 challenge.	 Frailty	 develops	 as	 a	 consequence	 of	 age‐related	 declines	 in	45 
many	physiological	systems,	resulting	in	vulnerability	to	stressors	(e.g.	infection	or	hospitalisation)	46 
and	adverse	health	outcomes.12	Fried	et	al.13	characterised	frailty	as	a	clinical	phenotype	of	at	least	47 
three	of	 five	 indicators:	 unintentional	weight	 loss,	 slow	walking	 speed,	 self‐reported	exhaustion,	48 
low	 levels	 of	 activity	 and	 muscle	 weakness.	 Frail	 individuals	 are	 at	 increased	 risk	 of	 falls,	49 
hospitalisation,	worsening	mobility,	disability	and	death.12	Frailty	has	also	been	linked	to	impaired	50 
global	cognition	and	cognitive	decline.14,15	Using	a	different	approach,	Rockwood	et	al.16	have	also	51 
characterised	 frailty,	 as	 an	 age‐associated,	 non‐specific	 accumulation	 of	 deficits	 resulting	 in	52 
vulnerability	to	stressors	and	adverse	outcomes.	They	present	this	accumulation	of	deficits	as	an	53 
index	score	called	the	frailty	deficit	index	(FI).		54 
Frail	 older	 adults	 are	 more	 susceptible	 to	 age‐	 and	 disease‐related	 changes	 in	 their	55 
pharmacokinetic	and	pharmacodynamic	responses	to	drugs.2,17	This	is	compounded	further	as	frail	56 
individuals	are	more	likely	to	be	administered	several	medications,	resulting	in	polypharmacy..17,18	57 
In	 community‐dwelling	 older	 people	 living	 in	 Finland,	 higher	 sedative	 load	was	 associated	with	58 
  
poorer	physical	performance,	balance	and	mobility.19,20	 In	contrast,	higher	sedative	 load	was	not	59 
associated	with	poorer	physical	or	cognitive	performance,	but	was	associated	with	impairments	in	60 
activities	of	daily	living	(ADLs)	and	Instrumental	ADLs	(IADLs)	among	community‐dwelling	older	61 
men	in	Australia.8	Data	regarding	the	direct	association	of	sedative	 load	and	 frailty	has	not	been	62 
published.		63 
In	 this	 study	 we	 assessed	 the	 potential	 relationship	 between	 sedative	 load	 exposure	64 
(independent	variable)	and	frailty	(dependent	variable)	measured	using	the	phenotype	and	deficit	65 
index	definitions.				66 
	67 
METHODS	68 
Study	population		69 
Cross‐sectional	analyses	were	performed	using	data	from	the	first	wave	of	The	Irish	Longitudinal	70 
Study	on	Ageing	 (TILDA)	conducted	between	2010‐2011.	The	TILDA	study	cohort	 includes	8,175	71 
participants	representative	of	the	community‐living	population	aged	50	and	older	living	in	Ireland.	72 
Households	were	selected	in	geographic	clusters	from	a	list	of	all	Irish	residential	addresses.	Each	73 
household	was	visited	by	an	interviewer	and	any	resident	aged	50	or	older	as	well	as	their	spouse	74 
or	partner	was	 invited	 to	participate.	The	household	 response	 rate	was	62.0%.	Ethical	 approval	75 
was	 obtained	 from	 the	 Trinity	 College	 Dublin	 Research	 Ethics	 Committee	 and	 all	 participants	76 
provided	 written	 informed	 consent.	 Those	 with	 cognitive	 impairment	 	 that	 prevented	 consent	77 
being	given	were	not	 included	 in	 the	 study	 for	ethical	 reasons.	Participants	were	 interviewed	 in	78 
their	 homes	 and	 answered	 questions	 on	 health,	 social	 interactions,	 and	 financial	 circumstances.	79 
Each	participant	was	 invited	to	 travel	 to	a	health	centre	 for	a	comprehensive	health	assessment.	80 
The	sampling	procedure,	 the	home	 interview,	and	 the	health	assessment	have	been	described	 in	81 
detail	previously.21	From	the	total	sample	of	8,175	participants,	3,446	aged	65	and	older	provided	82 
details	of	their	regular	medication	use	(Tables	1	and	2).	Of	these,	1,718	participants	attended	the	83 
health	 centre	 assessment	 and	 provided	 sufficient	 data	 to	 assess	 their	 frailty	 status	 (Table	84 
3).Assessment	of	sedative	load	(SL)	score	85 
  
The	 in‐home	 inventory	 of	 drugs	 and	 food	 supplements	 was	 conducted	 by	 asking	 the	86 
question	“Now	I	would	like	to	record	all	medications	that	you	take	on	a	regular	basis,	like	every	day	87 
or	 every	 week.	 This	 will	 include	 prescription	 and	 non‐prescription	 medications,	 over‐the‐counter	88 
medicines,	vitamins,	and	herbal	and	alternative	medicines.”	No	 information	about	dose,	 frequency,	89 
quantity	or	prescription	status	was	obtained.			90 
Drugs	 were	 coded	 using	 the	 ATC	 (Anatomical‐Therapeutic‐Chemical)	 classification	91 
system22	and	the	effect	of	taking	multiple	drugs	with	sedative	properties	was	calculated	using	the	92 
sedative	 load	model.3,11	Drugs	were	 categorized	 as:	 primary	 sedatives	 e.g.	 anxiolytics	 (Group	1);	93 
drugs	with	a	sedating	component	or	side	effect	e.g.	selective	serotonin	reuptake	inhibitors	(Group	94 
2);	drugs	with	sedation	as	a	potential	adverse	reaction	e.g.	acetylcholinesterase	inhibitors	(Group	95 
3);	all	other	medicines	with	no	known	sedative	properties	(Group	4).	Drugs	included	in	groups	1,2	96 
and	 3‐4	were	 assigned	 sedative	 ratings	 of	 2,	 1	 (Table	 2)	 and	 0	 respectively.	 Sedative	 load	was	97 
calculated	 as	 the	 sum	 of	 the	 sedative	 ratings	 at	 an	 individual	 level,	 for	 regularly	 used	 drugs.	98 
Sedative	Load	(SL)	scores	of	0,	1‐2	and	3	indicated	no,	low	and	high	sedative	load	respectively.	99 
The	sedative	 load	model	was	 first	published	 in	2003	and	was	updated	 in	2011.3,11	 In	our	100 
study,	this	model	was	assessed	and	modified	to	 include	drugs	taken	by	participants	 in	this	study	101 
and	 to	 reflect	 the	 current	 knowledge	 about	 sedative	 effects	 of	 drugs.	 Two  experienced  clinical 102 
pharmacists  (IM,JP)  independently consulted,  reviewed and amended scores  for  the original updated 103 
list of drugs11	using standard and widely accepted reference sources e.g. product characteristics (SmPC) 104 
information,  and  Maudsley  Prescribing  Guidelines23.  Relevant  MEDLINE  articles  24‐26  informed  the 105 
scoring of drugs not included on the list.	Scores	were	reviewed	by	an	experienced	psychogeriatrician	106 
and	 disagreements	were	 resolved	 by	 consensus.	 Drugs	 included	 in	 our	 analysis	with	 respective	107 
scoring	are	listed	in	Table	2.			108 
	109 
Frailty	Measures		110 
Phenotype	 frailty	 was	 operationalized	 using	 population‐specific	 cut‐points	 following	 the	111 
methodology	of	Fried	and	colleagues13.	This	was	done	owing	to	differences	in	the	assessments	of	112 
  
weakness	 (sex‐	and	bmi‐adjusted	grip‐strength	measured	using	baseline	dynamometer),	physical	113 
activity	 (sex‐adjusted	kilocalories	 (kcals)	 from	 the	 International	Physical	Activity	Questionnaire‐114 
Short	 Form	 [IPAQ‐SF]),	 and	 walking	 speed	 (sex‐	 and	 height‐adjusted	 cm/s	 using	 the	 GAITRite	115 
portable	 walkway)	 that	 made	 using	 the	 absolute	 cut‐points	 reported	 by	 Fried	 and	 colleagues	116 
inappropriate.	Weight	 loss	 was	 ascertained	 by	 the	 question	 “In	 the	 past	 year	 have	 you	 lost	 10	117 
pounds	(4.5	kg)	or	more	in	weight	when	you	were	not	trying	to.”	Exhaustion	was	captured	using	118 
two	 items	 from	 the	 20‐item	 Centre	 for	 Epidemiological	 Studies	 Depression	 (CES‐D)	 scale.		119 
Participants	were	asked	how	often	they	felt	that	“I	could	not	get	going”	and	“I	felt	that	everything	I	120 
did	 was	 an	 effort”.	 A	 response	 of	 “moderate	 amount/all	 of	 the	 time”	 to	 either	 question	 was	121 
considered	as	“exhaustion.”		The	presence	of	0,	1‐2	and	≥3	of	the	five	criteria	classified	participants	122 
as	non‐frail,	prefrail	(an	 intermediate	state)	and	frail,	respectively.	 	The	operationalization	of	 the	123 
frailty	phenotype	in	the	TILDA	cohort	at	Wave	1	has	been	described	previously.27,28		124 
Additionally,	 a	 frailty	 deficit	 index	 (FI)	 was	 constructed	 using	 40	 self‐reported	 health	125 
deficits	 from	 the	 TILDA	 home	 interview	 followed	 previously	 published	methodology	 (Appendix	126 
1).16,29	 The	 40	 deficits	 were	 associated	 with	 poor	 health,	 had	 a	 prevalence	 of	 5‐80%,	 were	127 
distributed	across	several	health	domains	and	were	associated	with	advancing	age.16	Each	deficit	128 
was	 coded	 as	 present	 (1)	 or	 absent	 (0).	 The	 total	 was	 then	 summed	 and	 divided	 by	 40.	 This	129 
produced	index	scores	between	0.0	and	1.0.		List	of	40	deficits	included	in	FI	is	in	Appendix.	130 
	131 
Demographic,	Health	and	Lifestyle	Measures		132 
Demographics	 included	 age,	 sex,	 education	 (reference	 group:	 secondary/higher)	 and	133 
marital	 status.	 The	 health	 measures	 recorded	 were:	 self‐rated	 health	 (Ecellent/Very	134 
good/Good/Fair/	Poor);	disability	(the	inability	to	perform	one	or	more	Instrumental/Activities	of	135 
Daily	Living	(IADL	or	ADL))30,31;	falls	(≥1	self‐reported	fall	in	the	past	year);	the	number	of	chronic	136 
diseases	 or	 conditions	 (recorded	 as	 self‐reported	 physician’s	 diagnosis	 of	 heart	 attack,	 heart	137 
failure,	angina,	hypertension,	high	cholesterol,	stroke,	diabetes,	lung	disease,	asthma,	arthritis	and	138 
osteoporosis);	 the	 number	 of	 all	 medications	 taken	 regularly	 (excluding	 supplements);	139 
underweight	(BMI	<18.5);	obese	(BMI	≥30);	self‐reported	difficulty	sleeping;	cognitive	impairment	140 
  
(MMSE	‐	Mini	mental	state	exam	score	≤24)32;	self‐rated	memory;	depressive	symptoms	(CES‐D	‐	141 
The	Center	 for	Epidemiologic	 Studies	Depression	 Scale	 score	≥16)33;	 anxiety	 (HADS‐A	 ‐	Hospital	142 
Anxiety	 and	 Depression	 Scale	 –	 Anxiety	 score	 	 ≥11)	 and	 loneliness.	 Life‐style	 factors	 included	143 
alcohol	consumption	(defined	as	a	yes/no	response	to	the	question	“Do	you	drink	alcohol?”)	and	144 
smoking	 status	 (defined	 as	 current/	 past/never	 based	 on	 two	 questions	 “Have you ever smoked 145 
cigarettes, cigars, cigarillos or a pipe daily for a period of at least one year?” and “Do you smoke at the 146 
present time?”).		147 
	148 
Statistical	analyses		149 
Demographic,	 health	 and	 lifestyle	 measures	 were	 presented	 as	 means	 and	 standard	150 
deviations	 or	 counts	 and	 percentages.	 Comparisons	 across	 different	 SL	 and	 frailty	 groups	were	151 
conducted	 using	 chi‐square	 test	 for	 categorical	 variables	 and	 analysis	 of	 variance	 (ANOVA)	 for	152 
continuous	variables	including	SL	score	and	FI	score.		153 
Multinomial	 logistic	 regression	 analyses,	 adjusted	 for	 demographic,	 health	 and	 lifestyle	154 
factors,	estimated	odds	ratios	(OR)	and	95%	confidence	interval	(CI)	 for	the	association	between	155 
SL	score	and	the	phenotype	frailty,	allowing	the	modelling	of	the	prefrail	and	frail	states	(reference	156 
group:	non‐frail).		157 
											 Multivariate	 linear	regression	was	used	 to	determine	associations	between	 the	SL	and	FI	158 
scores.	 Unstandardized	 regression	 coefficients	 (B)	 with	 95%	 CI	 were	 measured	 with	159 
accompanying	 p‐values.	 Analyses	 were	 adjusted	 for	 the	 same	 covariates	 listed	 above.	 Analyses	160 
were	performed	using	SPSS	18	(SPSS	for	Windows	Release	18.0).	161 
	162 
RESULTS	163 
Characteristics	of	the	study	population	and	sedative	load	(SL)	164 
Mean	(SD)	age	was	73.0	(±6.4)	years,	ranging	from	65	to	99	years	and	52.4%	were	female.	165 
Of	 the	 3,446	 participants,	 2,900	 (84.2%)	 reported	 taking	 at	 least	 one	 regular	 drug.	 Mean	 (SD)	166 
number	of	reported	drugs	was	3.3	(±2.7;	range	0	to	16)	per	participant.	Sedative	drugs	were	used	167 
  
by	668	(19.4%)	participants.	Mean	(SD)	sedative	load	was	0.41	(±1.00;	range	0	to	9).	Sedative	load	168 
was	higher	in	women	(0.50	[±1.09],	p≤0.001),	than	in	men	(0.32	[±0.88])	and	highest	in	the	75‐84	169 
years	 group	 (0.51	 ±1.11)	 compared	 to	 those	 aged	 65‐74	 years	 (0.36	 ±0.93)	 or	 ≥85	 years,	 (0.48	170 
±0.97)	respectively;	p≤0.001.	Detailed	characteristics	of	this	cohort	by	SL	are	provided	in	Table	1.	171 
The	most	 frequently	 used	primary	 sedatives	 (Group	1)	were	hypnotics	 (ATC	N05C),	 and	172 
drugs	most	 used	 with	 sedation	 as	 a	 prominent	 side	 effect	 (Group	 2)	 were	 SSRIs	 (ATC	 N06AB)	173 
within	 antidepressants.	 Cohort	 SL	 score	 was	 1,421.	 Hypnotics	 (ATC	 N05C)	 were	 the	 major	174 
contributor	with	an	overall	SL	score	of	450	ahead	of	antidepressants	(ATC	N06)	with	an	overall	SL	175 
score	of	350.		Details	of	sedative	drug	use	are	provided	in	Table	2.			176 
	177 
Prevalence	of	frailty	178 
Of	 the	 3,446	 participants,	 1,718	 attended	 the	 health	 centre	 assessment	 and	 provided	179 
sufficient	 data	 to	 assess	 their	 frailty	 status.	 	 The	 prevalence	 of	 frailty	 in	 this	 sample	 was	 4.2%	180 
(n=72),	39.1%	(n=672)	were	prefrail	 and	56.7%	(n=974)	were	non‐frail.	 Frail	 participants	were	181 
significantly	older,	had	more	chronic	diseases,	poorer	education	and	more	I/ADL	disability.	They	182 
had	 significantly	 higher	 drug	 use,	 polypharmacy	 (5≥	 drugs)	 and	 sedative	 drugs	 use.	 Prefrail	183 
participants	 were	 an	 intermediate	 group	 performing	 significantly	 worse	 on	 these	 measures	184 
compared	with	the	non‐frail	group	but	significantly	better	than	the	frail	group.	Sedative	drug	use	185 
was	at	46%	for	frail,	23%	for	prefrail	and	9%	for	non‐frail	participants.	More	women	were	prefrail	186 
or	 frail,	 but	 not	 significantly	 so.	 Mean	 FI	 score	 increased	 with	 frailty	 status	 through	 all	 three	187 
categories	(Table	3	and	Figure	1).	188 
	189 
The	relationship	between	frailty	and	sedative	load	(SL)	190 
Mean	SL	was	independently	associated	with	frailty	using	both	the	frailty	phenotype	and	FI	191 
models	as	shown	in	(Figure	1.	In	unadjusted	analyses,	frail	(OR	2.08,	95%CI	1.70‐2.54)	and	prefrail	192 
(OR	 1.63,	 95%CI	 1.43‐1.86)	 participants	 were	 significantly	 more	 likely	 to	 use	 medicines	 with	193 
sedative	properties	than	non‐frail	participants.	After	adjustment	for	all	listed	variables	in	Table	1,	194 
frailty	 (OR	1.30,	95%CI	1.02‐1.64;	p=0.023)	and	prefrailty	 (OR	1.27,	95%CI	1.11‐1.46;	p<0.001))	195 
  
remained	significantly	associated	with	SL	score.		196 
Multiple	 regression	 analysis	 was	 used	 to	 independently	 test	 if	 the	 SL	 was	 significantly	197 
correlated	with	FI	score.	 In	unadjusted	analyses	higher	FI	scores	were	associated	with	higher	SL	198 
cores	(=0.30;	p<0.001.	B=2.54;	95%	CI	2.15‐2.92).	The	adjusted	model	for	all	covariates	listed	in	199 
Table	1,	explained	10.4%	of	the	variance	(R2=0.104,	F(10.72)=124.64,	p≤0.001)	and	the	association	200 
between	SL	and	the	FI	score	was	significant	at	p≤0.001	(B=1.77;	95%	CI	1.13‐2.42).		201 
Respondents	who	did	not	provide	data	on	frailty	status	(n	=	1,728)	were	more	likely	to	be	202 
older,	less	educated,	took	more	medicines	and	had	a	higher	SL	at	p<0.05.	There	was	no	difference	203 
in	sex	or	number	of	comorbidites	reported	between	both	groups.	204 
	205 
DISCUSSION	206 
This	was	the	first	study	to	investigate	the	association	between	SL	and	frailty	in	community‐207 
dwelling	 adults	 aged	 65+	 years.	 Our	 data	 indicates	 the	 use	 of	 sedative	 drugs	 was	 positively	208 
associated	 with	 being	 both	 prefrail	 and	 frail	 in	 unadjusted	 and	 adjusted	 analyses	 using	 two	209 
established	methodologies	to	assess	frailty,	phenotype	frailty	and	the	FI.		210 
Our	findings	revealed	that	one	 in	 five	participants	 in	our	study	took	at	 least	one	sedative	211 
drug,	which	falls	between	the	Australian	and	Finnish	studies	where	15	%	and	29%	of	participants	212 
reported	 sedative	 drug	 use,	 respectively.3,8	 These	 differences	 may	 emerge	 from	 age/sex	213 
characteristics	 of	 the	 populations	 studied,	 their	 cultural	 background,	 environmental	 differences	214 
and	doctors’	prescribing	habits.		Those	who	reported	higher	SL	in	our	study	had	poorer	health	in	215 
line	with	previous	studies.	3,8	The	drugs	which	contributed	most	to	SL	in	our	study	were	hypnotics	216 
(Group	1)	and	SSRIs	with	other	antidepressants	(Group	2).	This	is	similar	to	the	Finnish	study3	but	217 
differs	 from	 the	 Australian	 study8,	 where	 anxiolytics	 (Group	 1)	 and	 antidepressants	 (Group	 2)	218 
were	the	major	contributors	to	overall	SL.	We	updated	the	original	Finnish	model	to	reflect	current	219 
knowledge	 regarding	 the	 sedative	 effect,	 as	 available	 from	 standard	 reference	 sources.	 The	220 
majority	of	changes	involved	re‐scoring	between	Groups	1	to	2,	and	only	lithium	moved	between	221 
the	categories	of	SL	and	no	SL.	We	believe	the	modified	model	better	reflects	the	sedative	burden	222 
  
of	 reported	drugs	and	both	 the	original	 and	modified	models	of	SL	were	 significantly	associated	223 
with	frailty	(Appendices	1	and	2).		224 
Frail	participants	in	our	cohort	were	older	and	had	poorer	health	indicators,	characteristic	225 
of	frailty	in	other	studies.12,13	Moreover,	the	respective	exposure	of	frail	and	prefrail	participants	to	226 
sedative	drugs	was	five	and	three	times	higher	compared	to	their	non‐frail	counterparts.	Adjusting	227 
for	relevant	confounders,	SL	was	significantly	associated	with	both	frailty	and	prefrailty.	For	each	228 
increase	 in	 SL	 score,	 the	 likelihood	 of	 being	 frail	 or	 prefrail	 increased	 by	 30%	 and	 27%,	229 
respectively.	While	a	clear	age	gradient	existed,	there	was	no	sex	difference	detected	in	our	sample	230 
despite	 reports	 that	 females	 are	more	 likely	 to	 be	 frail..13,34	 SL	was	 also	 significantly	 associated	231 
with	higher	FI	score.		232 
Loss	of	muscle	mass	and	function	(sarcopenia)	is	a	marker	of	frailty	and	may	be	influencing	233 
the	association	between	SL	and	frailty.	Similarly,	it	is	known	that	a	decrease	in	lower	limb	muscle	234 
mass,	strength	and	function	leads	to	poorer	gait	and	mobility.35	Thus,	the	association	between	SL	235 
and	 frailty	 may	 be	 explained	 by	 the	 adverse	 impact	 of	 sedative	 exposure	 on	 physical	 function,	236 
superimposed	on	a	sarcopenia‐related	frailty	process.	These	findings	could	have	important	clinical	237 
implications	with	respect	 to	prevention	of	other	adverse	health	outcomes	such	as	 falls,	 fractures	238 
and	disability.	These	adverse	outcomes	are	common	among	older	adults,	result	from	both	sedative	239 
drug	use	and	frailty	and	constitute	a	significant	burden	to	healthcare	systems	worldwide.	12,13,36,37	240 
This	suggests	that	minimising	sedative	exposure	in	prefrail	and	frail	older	adults	may	be	clinically	241 
significant	 given	 their	 increased	 vulnerability	 to	 adverse	 drug	 reactions	 and	 adverse	 health	242 
outcomes.	Longitudinal	and	intervention	studies	with	measures	of	sarcopenia,	frailty	and	SL	may	243 
help	to	better	 inform	these	relationships.	 Indeed	additional	 future	waves	of	the	TILDA	study	will	244 
contribute	 to	 our	 understanding	 of	 the	 impact	 of	 increasing	 sedative	 load	 exposure	 among	 the	245 
prefrail	and	frail.		246 
Polypharmacy,	high‐risk	treatment	regimens	and	the	Drug	Burden	Index	(an	alternate	tool	247 
to	 the	 SL	model)	were	previously	 associated	with	 frailty	 at	 baseline	 and	 incident	 frailty	 after	2‐248 
years.	 18,38	However,	 the	strengths	of	our	study	 included	the	use	of	a	 large	sample,	 that	was	very	249 
well	characterised	using	a	broad	range	of	epidemiologically	and	clinically	validated	measures.	Also,	250 
  
the	association	between	SL	and	frailty	was	confirmed	using	two	independent	and	methodologically	251 
different	measures	of	capturing	frailty,	lending	additional	support	to	the	relationship	between	SL	252 
and	 frailty.	 Furthermore,	 medication	 data	 was	 collected	 by	 trained	 interviewers	 in	 the	 home	253 
reducing	self‐report	recall	bias.39.	Few	methods	exist	to	measure	the	burden	of	sedative	drugs	but	254 
the	 advantages	 of	 the	 SL	 model	 are	 three‐fold:	 It	 includes	 drugs	 with	 sedative	 properties	255 
prescribed	for	somatic	diseases,	it	describes	cumulative	exposure	to	drugs	exerting	sedative	effects	256 
through	multiple	mechanisms	in	the	CNS,	and	it	incorporates	a	sedative	rating	for	each	drug.	3,8,19,20,			257 
There	were	some	limitations	of	the	study.	The	SL	model	has	not	been	validated	against	in	258 
vitro	or	 in	vivo	measures	of	sedative	activity,	or objective tests of altered psychomotor functioning.	259 
Drug	 dosage	 and	 frequency	 were	 not	 recorded.	 Only	 regularly	 taken	 drugs	 were	 included,	 not	260 
those	 taken	 ‘when	 required’	 (prn).	 There	may	 also	 be	 some	 limitation	 in	 terms	 of	 generalising	261 
findings	 in	 relation	 to	 the	 SL	 model,	 due	 to	 variations	 in	 the	 prescribing	 patterns	 of	 different	262 
countries	and	healthcare	systems.	To	provide	wider	generalizability	of	these	study	findings,	similar	263 
research	using	the	same	sedative	load	protocol	should	be	replicated	in	different	population.	 	The	264 
necessity	 to	 collect	 objective	 measurements	 of	 grip	 strength	 and	 walking	 speed	 in	 order	 to	265 
measure	 the	 frailty	phenotype	 status	 is	 also	a	potential	 limitation.	While	objective	measures	are	266 
considered	more	reliable	 than	self‐report	measures,	 they	are	often	 less	 feasible,	particularly	 in	a	267 
clinical	setting.	Indeed	participants	in	this	study	who	did	not	perform	a	health	assessment,	could	268 
not	 be	 assessed	 for	 frailty,	 although	 they	 were	 older,	 took	 more	 drugs,	 and	 had	 a	 higher	 SL.	269 
Similarly,	individuals	with	cognitive	impairment	that	prevented	informed	consent,	and	are	likely	to	270 
be	frail,	were	also	excluded	from	this	study.	 	This	suggests	that	our	estimation	of	the	association	271 
between	 sedatives	 and	 frailty	 may	 be	 conservative.	 Finally,	 cross‐sectional	 data	 do	 not	 allow	272 
assessment	of	 the	 causality	of	 the	 relationship	between	 frailty	and	SL.	 Some	of	 these	 limitations	273 
will	be	overcome	during	subsequent	waves	of	this	longitudinal	study	of	ageing.		274 
	275 
CONCLUSIONS	276 
The	 use	 of	 drugs	 with	 sedative	 properties	 in	 older	 Irish	 adults	 is	 significant	 and	 more	277 
prevalent	in	the	subpopulation	with	the	poorest	health	status.	In	this	study,	two	models	of	frailty	278 
  
were	 associated	 with	 higher	 SL.	 As	 frail,	 and	 prefrail,	 people	 are	 more	 susceptible	 to	 adverse	279 
responses	 to	 drugs	 and	 adverse	 health	 outcomes,	 additional	 consideration	 when	 choosing	280 
appropriate	 sedative	 drugs	 is	 needed	 in	 this	 vulnerable	 group.	 However,	 further	 studies	 are	281 
needed	to	assess	the	impact	over	time	of	greater	sedative	use	among	prefrail	and	frail	older	adults.	282 
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Table	1.	Participant	Characteristics	by	Sedative	Load	Category	(n=3,446)	431 
 432 
	
Total	
Population	 Sedative	Load	[n(%)]	
(n=3,446)	
[n(%)]	
(n=2,778)					
0	
(n=495)						
1	or	2	
(n=173)						
≥3	 P‐value	
Age	(Yrs)																					65‐74	 2,137	(62.0)	 1,771	(82.9)	 279	(13.1)	 87	(4.1)	
<0.001																																			75‐84	 1,091	(31.7)	 843	(77.3)	 172	(15.8)	 76	(7.0)	
																																				≥85	 218	(6.3)	 164	(75.2)	 44	(20.2)	 10	(4.6)	
Sex	(Female)	 1,804	(52.4)	 1,387	(49.9)	 310	(62.6)	 107	(61.8)	 <0.001
Education	(None/primary)		 1,514	(44.0)	 1,175	(42.3)	 255	(51.5)	 84	(48.6)	 <0.001
Married	 2,034	(59.0)	 1,708	(61.5)	 245	(49.5)	 81	(46.8)	 <0.001
Alcohol	users		 1,822	(63.1)	 1,516	(64.8)	 228	(55.9)	 78	(55.7)	 0.001	
Currently	smoking	 469	(13.6)	 357	(12.9)	 78	(15.8)	 34	(19.7)	 0.011	
No.	of	chronic	conditions	(Mean,	SD)	 2.21	(1.54)	 2.06	(1.46)	 2.76	(1.64)	 3.06	(1.87) <0.001
Self	rated	health	(Fair/Poor)		 564	(16.4)	 348	(12.5)	 152	(30.8)	 64	(37.0)	 <0.001
No.	of	drugs	(Mean,	SD)	 3.33	(2.71)	 2.79	(2.39)	 5.16	(2.60)	 6.86	(3.04) <0.001
IADL	disability	(≥1	disability)	 170	(4.9)	 121	(4.4)	 37	(7.5)	 12	(6.9)	 <0.001
ADL	disability	(≥1	disability)	 431	(12.5)	 262	(9.4)	 111	(22.4)	 58	(33.5)	 <0.001
Self	rated	memory	(Fair/Poor)	 705	(20.5)	 487	(17.5)	 153	(30.9)	 65	(37.6)	 <0.001
COPD/Asthma	 440	(12.8)	 319	(11.5)	 85	(17.2)	 36	(20.8)	 <0.001
MCI/Dementia	(MMSE score	≤24)	 245	(10.5) 175	(9.2) 50	(15.5)	 20	(15.7) <0.001
CVD	 1,993	(57.8)	 1,559	(56.1)	 319	(64.4)	 115	(66.5)	 <0.001
Arthritis	 1,304	(37.8)	 960	(34.6)	 241	(48.7)	 103	(59.5)	 <0.001
Stroke	 95	(2.8)	 53	(1.9)	 25	(5.1)	 17	(9.8)	 <0.001
Diabetes	 365	(10.6)	 276	(9.9)	 68	(13.7)	 21	(12.1)	 0.032	
Depression	(CES‐D	score	≥16)		 282	(8.4)	 165	(6.0)	 77	(16.0)	 40	(24.1)	 <0.001
Anxiety	(HADS‐A	score	≥	11)		 245	(9.0)	 157	(7.1)	 57	(15.2)	 31	(23.7)	 <0.001
Chronic	pain	(Moderate/severe)		 903	(26.2)	 591	(21.3)	 220	(44.5)	 92	(53.2)	 <0.001
Difficulty	sleeping	(Most	of	the	time)	 383	(11.1)	 245	(8.8)	 91	(18.4)	 47	(27.2)	 <0.001
Falls	(≥1	in	past	year)	 754	(21.9)	 551	(19.8)	 137	(27.7)	 66	(38.2)	 <0.001
Loneliness		
(moderate/most	of	the	time)		 285	(8.3)	 190	(6.8)	 62	(12.5)	 33	(19.2)	 <0.001
	
I/ADL	–	Instrumental/Activities	of	Daily	Living.	
COPD	–	Chronic	Obstructive	Pulmonary	Disease.	
MCI	–	Mild	Cognitive	Impairment.	
MMSE	–	Mini	Mental	State	Examination		
CVD	‐	Cardiovscular	disease	(high	blood	pressure,	atrial	fibrillation,	transient	ischemic	attack).	
CES‐D	–	Center	for	Epidemiological	Studies	–Depression	scale.	
HADS‐A	–	Hospital	Anxiety	and	Depression	Scale	–	Anxiety	module.	433  434 
 435 
  
Table	2.	Categorisation	of	Drugs	Contributing	to	Sedative	Load	in	the	Cohort	(n=3,446)	436 
 437 
	
#	Drug	is	included	in	“group	1”	(SL	score	2)	
	
Group	 ATC	 INN	Reported	by	Participants	 N	 %	
Antidepressants	 N06A	
clomipramine#,	trimipramine#,	lofepramine#,	
amitriptyline#,	dothiepin#,fluoxetine,	
citalopram,	paroxetine,	sertraline,	
escitalopram,	trazodone#,	mirtazapine#,		
venlafaxine,	duloxetine	 265	 7.7%	
Hypnotics	 N05C	
flurazepam#,	nitrazepam#,	flunitrazepam#,	
lormetazepam#,	temazepam#,	zopiclon#,	
zolpidem#,	zaleplon#	 223	 6.5%	
Opioid	analgesics	 N02A	
morphine,	oxycodone,	dihydrocodeine,	
codeine	(also	combinations),	fentanyl,	
dextropropoxyphene,	buprenorphine,	
tramadol	(also	combinations),	meptazinol	 133	 3.9%	
Antiepileptics	 N03	
phenobarbital#,	primidone,	phenytoin,	
clonazepam#,	carbamazepine,	valproic	acid,	
tiagabine,	lamotrigine,	gabapentin#,	
levetiracetam,	pregabalin#	 125	 3.6%	
Anxiolytics	 N05B	
diazepam#,	chlordiazepoxide#,	lorazepam#,	
bromazepam#,	clobazam#,	prazepam#,	
alprazolam#	 88	 2.6%	
Antipsychotics	(both	
conventional&atypical)	 N05A	
chlorpromazine#,	prochlorperazine#,	
sulpiride,	olanzapine#,	quetiapine#,	
risperidone	 42	 1.2%	
Propulsives	 A03FA	 Domperidone		 21	 0.6%	
Anti‐Parkinson	Drugs	 N04	 biperiden,	ropinirole,	pramipexole,	rotigotine	 12	 0.3%	
Muscle	relaxants	 M03BX	 baclofen,	tizanidine 6	 0.2%	
Other	 		
clonidine,	cinnarizine,	zolmitriptan,	valerian	
extract#	 8	 0.2%	
Opioid	antitussives	 R05DA		 codeine,	dextromethorphan,	dihydrocodeine	 4	 0.1%	
Antihistamine	 R06	 chlorphenamine,	promethazine#	 3	 0.1%	
No	of	respondents	
reporting	at	least	one	
drug	with	SL≥1	 		
668	 19.4%	
438 
 439 
 440 
	441 
	442 
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	444 
  
Table	 3.	 Modified	 Sedative	 load,	 and	 participant	 characteristics,	 by	 frailty	 phenotype	445 
status	(n=1,718)	446 
 447 
	448 
Independent	Variables	 Frailty	Phenotype	Status	
	
Robust					 		
974	(56.7)	
Prefrail								
672	(39.1)	
Frail											 			
72	(4.2)	
Frailty	Index	(FI)	score	(Mean,	SD)	 0.11	(0.08)	 0.18	(0.11)**	 0.32	(0.12)**	
Exposure	to	sedative	drugs	(SL	≥1)	 84	(8.6)	 153	(22.8)**	 33	(45.8)**	
Sedative	load	score	(Mean,	SD)			 0.17	(0.65)	 0.50	(1.05)**	 0.89	(1.22)**	
Age	(Mean,	SD)	 70.12	(4.44) 72.45	(5.56)**	 76.17	(6.59)**	
Sex	(Female)	 476	(48.9)	 361	(53.7)	 40	(55.6)	
Education	(none/primary)	 291	(29.9)	 237	(35.3)*	 30	(41.7)*	
Married	 719	(73.8)	 438	(65.2)**	 39	(54.2)**	
Rx	medication	exposure	 766	(78.6)	 584	(86.9)**	 71	(98.6)**	
No.	of	drugs	(Mean,	SD)	 2.53	(2.28)	 3.69	(2.74)**	 5.46	(2.89)**	
No.	of	chronic	diseases	(Mean,	SD)	 1.93	(1.37)	 2.39	(1.57)**	 3.60	(1.67)**	
Polypharmacy	(≥5	of	drugs)	 176	(18.1)	 236	(35.1)**	 39	(54.2)**	
IADL	disability	(≥1)	 13	(1.3)	 26	(3.9)**	 10	(13.9)**	
ADL	disability	(≥1)	 45	(4.6)	 89	(13.2)**	 29	(40.3)**	
Global	Cognitive	Function	(Mean	MMSE	score,	SD)	 28.41	(1.77) 28.00	(2.17)**	 27.08	(2.66)**	
Depression	(CES‐D	≥	16)	 26	(2.7)	 62	(9.5)	**	 21	(29.6)	**	
Anxiety	(HADS	A	≥	11)	 50	(5.5)	 66	(10.9)	**	 10	(17.2)	**	
	449 
I/ADL	–	Instrumental/Activities	of	Daily	Living.	450 
MMSE	–	Mini‐Mental	State	Examination.	451 
CES‐D	–	Center	for	Epidemiological	Studies	–Depression	scale.	452 
HADS‐A	–	Hospital	Anxiety	and	Depression	Scale	–Anxiety	schedule.	453 
*p<0.05,	**p<0.001	454 
 455 
	456 
 457 
  
 458 
Figure	1.	Unadjusted	mean	sedative	load	(SL)	score	was	associated	with	prefrailty,	frailty	459 
and	frailty	index	score	(FI)	among	participants	aged	65+	years	(n=1,718).	460 
**p<0.001	461 
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Appendix	I.	Adjusted	model	of	association	between	the	modified	sedative	load	(SL)	score	496 
and	frailty	phenotype	status	(n=1,718).	497 
	498 
Variable  Category  Prefrail Frail 
      Adjusted OR  [95% CI] 
p-
value 
Adjusted OR  
[95% CI] 
p-
value 
Sedative load (SL) score [continuous variable] 1.31 (1.14-1.51) ≤0.001 1.43 (1.08-1.90) 0.014 
Age (years)          [continuous variable] 1.10 (1.08-1.13) ≤0.001 1.29 (1.21-1.37) ≤0.001
Depression [continuous variable] 1.08 (1.05-1.10) ≤0.001 1.17 (1.11-1.24) ≤0.001
Cognitive impairment  [continuous variable] 0.90 (0.84-0.96) ≤0.001 0.85 (0.74-0.97) 0.020 
Sex                 Male 1   1   
                        Female 1.16 (0.91-1.49) 0.229 0.96 (0.49-1.86) 0.901 
Education     Secondary or higher 1   1   
                      None/Primary 0.84 (0.65-1.08) 0.173 0.63 (0.31-1.27) 0.197 
CVD             No 1   1   
                          Yes 1.07 (0.85-1.35) 0.577 1.67 (0.77-3.60) 0.192 
Stroke              No 1   1   
                         Yes 2.83 (1.16-6.88) 0.022 7.22 (1.89-27.58) 0.004 
Diabetes       No 1   1   
                       Yes 2.07 (1.38-3.11) ≤0.001 1.95 (0.77-4.95) 0.159 
Arthritis         No 1   1   
                         Yes 1.20 (0.94-1.53) 0.150 2.05 (1.04-4.03) 0.037 
COPD/asthma        No 1   1   
                                Yes 0.94 (0.67-1.34) 0.749 1.32 (0.60-2.91) 0.490 
Smoking  Never 1   1   
  Current smoker 1.45 (0.96-2.19) 0.076 3.84 (1.40-10.55) 0.009 
  Past smoker 1.09 (0.85-1.40) 0.506 1.32 (0.63-2.76) 0.464 
Alcohol consumption     No 1   1   
                                       Yes 0.77 (0.60-0.99) 0.044 0.82 (0.41-1.64) 0.576 
BMI<18.5 and >30)           No 1   1   
         Yes 1.32 (1.03-1.69) 0.029 1.40 (0.70-2.82) 0.344 
Disability ADL              None 1   1   
  ≥1 ADL 2.23 (1.44-3.46) ≤0.001 4.14 (1.86-9.21) ≤0.001
  ≥1 IADL 2.15 (0.99-4.64) 0.052 7.07 (2.12-23.55) 0.001 
Self-rated health      
Excellent/Very 
good/Good 1   1   
  Fair/Poor 2.54 (1.63-3.94) ≤0.001 11.90 (5.52-25.66) ≤0.001
Loneliness     None of the time 1   1   
  Most of all of the time 0.86 (0.50-1.47) 0.578 0.79 (0.28-2.21) 0.658 
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Appendix	2.	Adjusted	model	of	association	between	the	original	sedative	load	(SL)	score	504 
and	frailty	phenotype	status	(n=1,718).	505 
	506 
Variable Category Prefrail Frail 
    
Adjusted OR 
[95% CI] 
p-   
value 
Adjusted OR  [95% 
CI] 
p-
value 
Sedative load score [continuous variable]  1.35 (1.16-1.56) ≤0.001 1.49 (1.10-2.01) 0,010 
Age (years)          [continuous variable]  1.10 (1.08-1.13) ≤0.001 1.29 (1.21-1.37) ≤0.001
Depression [continuous variable]  1.08 (1.05-1.10) ≤0.001 1.17 (1.11-1.23) ≤0.001
Cognitive impairment [continuous variable]  0.90 (0.84-0.96) ≤0.001 0.85 (0.74-0.98) 0,021 
Sex Male  1   1   
         Female  1.16 (0.91-1.48) 0,242 0.96 (0.49-1.86) 0,891 
Education       Secondary or higher  1   1   
                   None/Primary  0.84 (0.65-1.09) 0,181 0.63 (0.31-1.28) 0,202 
CVD            No  1   1   
  Yes  1.07 (0.85-1.36) 0,558 1.68 (0.78-3.62) 0,188 
Stroke        No  1   1   
  Yes  2.83 (1.16-6.89) 0,022 7.20 (1.88-27.54) 0,004 
Diabetes      No  1   1   
  Yes  2.09 (1.39-3.14) ≤0.001 1.98 (0.78-5.01) 0,152 
Arthritis       No  1   1   
  Yes  1.20 (0.94-1.54) 0,138 2.06 (1.05-4.05) 0,035 
COPD/asthma      No  1   1   
                                  Yes  0.95 (0.67-1.35) 0,770 1.34 (0.61-2.94) 0,474 
Smoking Never  1   1   
  Current smoker  1.45 (0.96-2.18) 0,079 3.81 (1.39-10.45) 0,010 
  Past smoker  1.09 (0.84-1.39) 0,524 1.30 (0.62-2.73) 0,486 
Alcohol consumption   No  1   1   
  Yes  0.78 (0.60-1.00) 0,051 0.83 (0.42-1.66) 0,602 
BMI<18.5 and >30)          No  1   1   
                      Yes  1.32 (1.03-1.69) 0,027 1.41 (0.70-2.84) 0,334 
Disability ADL        None  1   1   
  ≥1 ADL  2.21 (1.43-3.44) ≤0.001 4.10 (1.84-9.12) ≤0.001
  ≥1 IADL  2.16 (1.00-4.67) 0,050 7.08 (2.12-23.62) ≤0.001
Self-rated health 
Excellent\Very 
good\Good  1   1   
  Fair\Poor  2.53 (1.63-3.93) ≤0.001 11.88 (5.51-25.62) ≤0.001
Loneliness    None of the time  1   1   
                All or most of the time  0.87 (0.51-1.50) 0,624 0.81 (0.29-2.26) 0,690 
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